Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
Colman et al v. Theranos, Inc. et al
Case Number:
5:16-cv-06822
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Bleichmar Fonti
- Cooley LLP
- Dynamis LLP
- Hagens Berman
- Keker Van Nest & Peters
- Payne & Fears
- Robbins Geller
- Ross Aronstam
- Sheppard Mullin
- WilmerHale
Companies
Sectors & Industries:
-
April 19, 2017
Indirect Share Purchasers Cleared To Sue Theranos
Investors who purchased Theranos Inc. stocks through a third party can sue the company for securities fraud, and the investment firms that brokered the deals may be on the hook for fraud too, a California federal judge said on Tuesday.
-
April 07, 2017
Theranos Investors Can't Delay Class Action-Ending Deal
A California federal judge refused Friday to push back a deadline for Theranos shareholders to agree to a deal that would resolve class allegations the company misled investors about the accuracy of its blood tests, finding that notices from the beleaguered startup disclosing terms of the deal aren't coercive or misleading.
-
March 01, 2017
Theranos Says Investors Can't Sue Over Blood Tests
Beleaguered blood-testing startup Theranos and its executives urged a California federal judge Wednesday to toss a putative securities class action alleging they misled investors about the accuracy of Theranos' tests, saying the investors can't sue them because they didn't buy their securities directly from Theranos.
-
November 28, 2016
Theranos Stuck By Investor Suit Saying It Lied About Testing
Investors led by Silicon Valley venture capital financier Robert Colman accused Theranos and its executives of violating securities and competition laws by hiding from the public that its blood testing technology promises had fallen through in a proposed class action filed Monday in California federal court.
- ← Previous
- 1
- 2
- Next →